Questions linger over Biogen's tau drug for Alzheimer's, as low dose reports better results on July 15, 2026 Alzheimer 's disease Biogen CDR-SB CELIA Phase 2 trial diranersen dose-response Low dose Mental deterioration Pathology Phase 3 questions uridine triacetate +
FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts on April 30, 2025 Agencies Approved Impact food supplement PDUFA questions United States Food and Drug Administration +